9 February 2018 - The recommendations from the December 2017 PBAC meeting are now available.

The PBAC recommended the following medicines:

• Adalimumab (Humira)
  
• Cabozantinib maleate (Cabometyx)
  
• Fluticasone furoate with vilanterol trifenatate and umeclidinium bromide (Treligy Elipta)
  
• Tenofovir disoproxil fumarate with emtricitabine (Truvada, Tenofovir disoproxil emtricitabine Mylan, Tenofovir EMT GH)
• Brentuximab vedotin (Adcetris)
  

Read PBAC outcomes